SoundHealth Raises $12.25M to Accelerate Growth of Its AI-Enabled Non-Invasive Devices for Breathing and Sleep Disorders

Oversubscribed Series A led by Shangbay Capital brings total funding to date to $12.25M, fueling expansion of the company's FDA-cleared, personalized therapeutics

SAN FRANCISCO--(BUSINESS WIRE)--SoundHealth, a leader in personalized, AI-enabled non-invasive medical and wellness devices, announced the closing of an oversubscribed Series A financing led by Shangbay Capital, bringing the company's total funding to date to $12.25 million. The new capital will accelerate growth of SoundHealth's portfolio of personalized, FDA-cleared therapeutics designed to treat population scale breathing; and wellness devices targeted towards sleep disorders.

SoundHealth's devices combine clinically validated science with proprietary AI to deliver personalized, drug-free treatment at scale. The company's flagship product, the FDA-cleared Sonu band, has now delivered more than 500,000 acoustic resonance treatment sessions for users ages 12 and up. Additionally, the flagship product has become the leading steroid alternative for the treatment of congestion due to allergic and non-allergic rhinitis.

The company's industry-leading craniofacial anatomical dataset was developed to deliver personalized treatment for congestion. This unique craniofacial anatomical dataset has been used to provide the foundation for the company’s Spatial Sleep product, the world's first clinically proven personalized sleep wellness device. Spatial Sleep has been shown to help people fall asleep faster and sleep longer.

Recommended by more than 1,000 medical and dental professionals nationwide, SoundHealth is leading the industry in revolutionizing non-drug treatments for breathing and sleep disorders.

“We are excited to work with Shangbay Capital to help accelerate the growth of our business,” said Dr. Paramesh Gopi, CEO of SoundHealth.

“Shangbay's deep expertise in scaling medtech companies will benefit our growth trajectory. We are thrilled to have them as our Series A lead investor,” said Dr. Bryant Lin, Co-Founder of SoundHealth.

“We are excited to invest in SoundHealth's portfolio of non-invasive, FDA-cleared, AI-enabled therapeutics that address large, population-scale problems,” said William Dai, Founder of Shangbay Capital. “Their unparalleled dataset and proprietary algorithms have tremendous potential going forward.”

About SoundHealth

SoundHealth is a medical technology company developing personalized, AI-enabled, non-invasive devices that treat population-scale breathing and sleep disorders. SoundHealth is recommended by more than 1,000 professionals nationwide. To learn more, visit www.soundhealth.life.